RxDoctor Payments Data

Lissette Toro

Primary Care · Woodhaven, NYNPI 1811616824

Payments from drug & device makers

$885in general payments, 2019–2025

Across 28 payments — averaging $31.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$366
  • Novo Nordisk$223
  • Exact Sciences$83
  • Bayer$71
  • Boehringer Ingelheim$43
  • GSK$41
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$366
Novo Nordisk5$223
Exact Sciences4$83
Bayer3$71
Boehringer Ingelheim2$43
GSK2$41
Lilly USA, LLC1$23
Pfizer1$18
BD1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$885 in reported general payments places this provider in the 65th percentile of 239 primary care providers in New York.

See all primary care providers in New York

Medicare billing

Part B allowed, 2024
$35,706
Medicare patients
83
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate56$64,130
EliquisApixaban41$43,995
Diclofenac Sodium70$36,414
JardianceEmpagliflozin24$32,650
FarxigaDapagliflozin Propanediol21$27,847
EntrestoSacubitril/Valsartan22$22,063
Lidocaine124$17,133
Breo ElliptaFluticasone/Vilanterol39$15,810
Albuterol Sulfate HfaAlbuterol Sulfate506$15,162
XareltoRivaroxaban11$13,789
VascepaIcosapent Ethyl38$12,922
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$11,904
RestasisCyclosporine11$6,769
SymbicortBudesonide/Formoterol Fumarate20$4,404
Atorvastatin Calcium432$4,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$43,99541 claims
Boehringer IngelheimJardiance$43$32,65024 claims
AstraZenecaFarxiga, Symbicort$366$32,25141 claims
GSKBreo Ellipta, Shingrix$41$18,30451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 239 primary care providers in New York.

Other primary care in Woodhaven

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →